UnitedHealthcare Xolair Prior Auth Policy Update

Coverage Criteria for Omalizumab (Xolair)

Initial authorization — moderate to severe persistent asthma

Covered when ALL of the following are met

Established therapy: Patient has been established on therapy with Xolair for moderate to severe persistent asthma under an active UnitedHealthcare medical benefit prior authorization

Clinical response documentation: Documentation of positive clinical response to Xolair as shown by at least one: reduction in exacerbations; increased percent predicted FEV1 from baseline; decreased rescue medication use; reduction in symptom severity/frequency

Concomitant therapy: Xolair will be used in combination with an ICS-containing regimen: either one maximally dosed ICS-LABA combination product OR one maximally dosed ICS plus one additional asthma controller medication

Examples: Advair/AirDuo, Symbicort, Breo Ellipta, or alternate maximally dosed ICS plus a LABA, leukotriene receptor antagonist, or theophylline.

Exclusions - concurrent biologics: Patient is not receiving Xolair in combination with anti‑interleukin‑4 therapy (eg, dupilumab), thymic stromal lymphopoietin (TSLP) inhibitor (eg, tezepelumab), or anti‑interleukin‑5 therapies (eg, mepolizumab, reslizumab, benralizumab)

Disease control: Asthma is uncontrolled or inadequately controlled as defined by at least one: ACQ >1.5 or ACT <20; asthma-related ER/hospital/unscheduled urgent visit; ≥2 bursts of systemic corticosteroids (≥3 days each) in prior 12 months; airflow limitation with reduced FEV1/FVC; dependence on oral corticosteroids

Allergic sensitization and IgE: Baseline pre‑omalizumab serum total IgE ≥ 30 IU/mL (and below the upper limit per dosing guidance) AND positive skin test or in‑vitro reactivity to a perennial aeroallergen

Submission of medical records documenting baseline IgE and testing required.

Reauthorization — asthma

Reauthorization requires ALL of the following

Clinical response: Documentation of positive clinical response to Xolair therapy demonstrated by at least one: reduction in frequency of exacerbations; decreased utilization of rescue medications; reduction in severity or frequency of asthma‑related symptoms

Concomitant therapy and exclusions: Continued use with an ICS‑containing maintenance medication AND patient is not receiving Xolair in combination with anti‑IL‑4, anti‑IL‑5, or TSLP inhibitor therapies

Initial authorization — chronic spontaneous urticaria (CSU)

Covered when ALL of the following are met

Established therapy: Patient has been established on therapy with Xolair for chronic urticaria under an active UnitedHealthcare medical benefit prior authorization OR diagnosis of chronic urticaria

Clinical response: Documentation of positive clinical response to Xolair therapy (e.g., reduction in itch severity, hives)

Prior antihistamine therapy: Patient remains symptomatic despite at least a 2‑week trial of a second‑generation H1‑antihistamine OR remains symptomatic despite trial/intolerance/contraindication to combination therapy including a second‑generation H1 as specified

Examples include fexofenadine, loratadine, cetirizine; combination options and alternatives listed in policy.

Adjunct therapies tried: Trial of alternative/additional agents such as a different second‑generation H1, an H2‑antihistamine, or a first‑generation H1 as listed in the policy

Reauthorization — chronic spontaneous urticaria (CSU)

Reauthorization requires ALL of the following

Clinical response: Documentation of positive clinical response to Xolair therapy (e.g., reduction in itch severity, hives)

Required for reauthorization

Nasal polyps — Initial and Reauthorization

Covered when ALL of the following are met for initial authorization or reauthorization as specified:

Indication and prior authorization: Patient has been established on therapy with Xolair for nasal polyps under an active UnitedHealthcare medical benefit authorization OR meets initial use criteria

(initial authorization requires established therapy under medical benefit or meeting diagnostic criteria)

Symptom duration and findings: Symptoms (eg, nasal mucopurulent discharge; facial pain/pressure/fullness; nasal obstruction or congestion; reduction/loss of smell) for longer than 12 weeks AND objective endoscopic or CT findings (eg, purulent mucus/edema in middle meatus or ethmoid, polyps in nasal cavity/middle meatus, or radiographic mucosal thickening/opacification)>=12 weeks

Prior therapy or severity: Either failed trials of intranasal corticosteroids and one other therapy used in management of nasal polyps (eg, saline irrigations, antileukotriene agents) OR required systemic corticosteroids in past 2 years OR prior sinus surgery

Chronic spontaneous urticaria / other dermatologic indications — Reauthorization

Reauthorization covered when ALL of the following are met:

Documented clinical response: Documentation of positive clinical response to Xolair therapy (eg, reduction in exacerbations, itch severity, hives)

Required for reauthorization

Concomitant biologic exclusion: Patient is not receiving Xolair in combination with anti‑IL‑4, anti‑IL‑5 agents, or TSLP inhibitors

Prescriber type: Prescribed by an Allergist, Immunologist, or Dermatologist

IgE-mediated food allergy — Initial and Reauthorization

Covered when ONE of the following pathways is met (established on therapy under medical benefit OR meets initial diagnostic and safety criteria):

Established therapy pathway: Patient has been established on therapy with Xolair for IgE‑mediated food allergy under an active UnitedHealthcare medical benefit authorization

Initial diagnostic pathway: Diagnosis of IgE‑mediated food allergy to one or more foods confirmed by history of type I allergic reaction AND one confirmatory test: serum specific IgE in vitro testing, food‑specific skin prick testing, or oral food challenge

Adjunctive measures: Xolair will be used in conjunction with food allergen avoidance and the patient has access to epinephrine

Concomitant biologic exclusion and prescriber: Patient is not receiving Xolair in combination with anti‑IL‑4, anti‑IL‑5, or TSLP inhibitor therapies; prescribed by an allergist or immunologist

Initial Therapy

Covered when ALL of the following are met

Initial Authorization for IgE‑mediated food allergy: Either: (A) Prescribed by an allergist or immunologist; OR (B) All of the following: diagnosis of IgE‑mediated food allergy to one or more foods; confirmation by history of type I allergic reactions plus one of: serum specific IgE, food‑specific SPT, or oral food challenge; Xolair will be used in conjunction with food allergen avoidance; patient has access to epinephrine; patient is not receiving Xolair in combination with anti‑IL‑4, anti‑IL‑5, or TSLP inhibitor therapies; AND patient is ≥ 2 years of age.age >= 2 years

Prescriber requirement appears both as standalone and repeated in sections.

Continuation Therapy / Reauthorization

Covered when ALL of the following are met

Reauthorization: Documentation of positive clinical response to Xolair therapy (eg, reduction in type I allergic reactions); Xolair used in conjunction with food allergen avoidance; patient has access to epinephrine; patient is not receiving Xolair in combination with listed biologics; AND prescribed by an allergist or immunologist where required.authorization duration 12 months

Authorization will be issued for 12 months; tried/failed alternatives supported by FDA labeling.

Omalizumab is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and is not indicated for acute bronchospasm or status asthmaticus. Use of Xolair in these acute or emergency settings is outside the scope of coverage and may result in denial.

The policy explicitly addresses combination use: Xolair must not be used concurrently with other specified biologic therapies. Across indication-specific sections the requirement that the patient is not receiving Xolair in combination with anti‑IL‑4, anti‑IL‑5 agents, or a TSLP inhibitor is repeated and enforced as a condition of approval.

Concomitant therapy exclusions apply to the following biologics: anti‑interleukin‑4 therapy (e.g., dupilumab), anti‑interleukin‑5 therapies (e.g., mepolizumab, reslizumab, benralizumab), and thymic stromal lymphopoietin (TSLP) inhibitors (e.g., tezepelumab). Patients receiving any of these agents in combination with Xolair do not meet the policy’s coverage criteria.

Requests to approve simultaneous use of Xolair with the listed biologics are not permitted under this policy and may be denied. The policy language appears in multiple indication sections and establishes combination‑therapy requests involving anti‑IL‑4, anti‑IL‑5, or TSLP inhibitors as a basis for noncoverage.

Coverage for continued Xolair therapy is contingent on documentation of a positive clinical response. Reauthorization requires evidence such as reduction in exacerbations or allergic reactions, decreased rescue medication use, or improvement in symptom severity/frequency; absent documented response, continuation may be considered not medically necessary.

Provider Actions, Requirements, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization required for initial and continuing Xolair (omalizumab) therapy. Initial approvals require documentation that the patient meets indication-specific diagnostic and treatment criteria. Automated approvals may be granted based on prior claim/medication history and diagnosis codes per UnitedHealthcare program rules.

Prior authorization is required for initiation and reauthorization of Xolair for all indications.
Automated approval and re-approval processes may be used when prior claim/medication history, ICD-10 diagnosis codes, and claim logic demonstrate meeting criteria; program use varies by therapeutic class and region.
Supply limitations may apply and FDA-labeled requirements/support (including step or prior therapy where specified) are enforced.

Documentation Required

Required Clinical Documentation

Providers must document diagnostic confirmation and treatment response per indication. Submission of medical records (chart notes, lab results, testing) is required to support initial and continuing use.

Coding and Laboratory Thresholds

Serum total IgE — baseline requirement

Serum total IgE baselineGreater than or equal to 30 IU/mL (and less than the upper limit per dosing guidance)

Required documentationSubmission of medical records documenting baseline (pre-omalizumab) serum total IgE level

Context of useBaseline IgE requirement applies to moderate to severe persistent asthma initial authorization

Definitions and Clinical Terms

Indications and limitations — FDA indications summary

FDA‑listed indication — CRSwNPChronic rhinosinusitis with nasal polyps (CRSwNP) in adults ≥18 years as add‑on maintenance with inadequate response to nasal corticosteroids

FDA‑listed indication — AsthmaModerate to severe persistent asthma in adults and pediatric patients (age partially redacted) with positive skin test or in vitro reactivity to a perennial aeroallergen and inadequately controlled on inhaled corticosteroids

FDA‑listed indication — Food allergyIgE‑mediated food allergy in patients ≥1 year to reduce Type I allergic reactions, including anaphylaxis, used with allergen avoidance

FDA‑listed indication — CSUChronic spontaneous urticaria in adults and adolescents ≥12 years who remain symptomatic despite H1 antihistamines

Limitations of useNot indicated for emergency treatment of allergic reactions/anaphylaxis or for acute bronchospasm/status asthmaticus

Background

Omalizumab (Xolair) is an anti‑IgE monoclonal antibody that binds circulating IgE to reduce downstream allergic inflammation. FDA‑approved indications include treatment of moderate to severe persistent asthma with allergic sensitization, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and, as recently added, IgE‑mediated food allergy (used with allergen avoidance and epinephrine access). The agent is not indicated for emergency management of anaphylaxis or acute bronchospasm.

OpenPayer

Omalizumab (Xolair) prior authorization and medical necessity

Coverage Criteria for Omalizumab (Xolair)

Provider Actions, Requirements, and Documentation

Coding and Laboratory Thresholds

Definitions and Clinical Terms

Background